Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that results from a large, well-controlled pharmacogenomics study in patients with major... read more
Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that results from a large, well-controlled pharmacogenomics study in patients with major... read more
Evolve Biologics, a division of Therapure Biopharma Inc., announced on 5/4/18 that it has dosed the first pediatric patient in its Phase III multicenter clinical trial of PlasmaCap IG (... read more
Boehringer Ingelheim announced on 5/4/18 that Praxbind (idarucizumab), a specific reversal agent for Pradaxa (dabigatran etexilate mesylate), is now stocked in 3,200 hospitals in all 50 states.... read more
The FDA extended the PDUFA goal date of Akcea's hereditary TTR amyloidosis drug inotersen to October 6, 2018.
“The FDA has extended the review period for TEGSEDI and has assigned a new... read more
Integer Holdings Corporation (“Integer”) (NYSE:ITGR), a leading medical device outsource manufacturer, today announced that it has entered into an agreement to sell its Advanced Surgical and... read more